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Background: Urokinase (uPA) and its receptor (uPAR) play an important role in tumour growth and metastasis, and
overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours.
Targeting the excessive activation of this system as well as the proliferation of the tumour vascular endothelial cell
would be expected to prevent tumour neovasculature and halt tumour development. The amino terminal fragment
(ATF) of urokinase has been confirmed effective to inhibit the proliferation, migration and invasiveness of cancer
cells via interrupting the interaction of uPA and uPAR. Triptolide (TPL) is a purified diterpenoid isolated from the
Chinese herb Tripterygium wilfordii Hook F that has shown antitumor activities in various cancer cell types. However,
its therapeutic application is limited by its toxicity in normal tissues and complications caused in patients. In this
study, we attempted to investigate the synergistic anticancer activity of TPL and ATF in various solid tumour cells.
Methods: Using in vitro and in vivo experiments, we investigated the combined effect of TPL and ATF at a low
dosage on cell proliferation, cell apoptosis, cell cycle distribution, cell migration, signalling pathways, xenograft
tumour growth and angiogenesis.
Results: Our data showed that the sensitivity of a combined therapy using TPL and ATF was higher than that of
TPL or ATF alone. Suppression of NF-κB transcriptional activity, activation of caspase-9/caspase-3, cell cycle arrest,
and inhibition of uPAR-mediated signalling pathway contributed to the synergistic effects of this combination
therapy. Furthermore, using a mouse xenograft model, we demonstrated that the combined treatment completely
suppressed tumour growth by inhibiting angiogenesis as compared with ATF or TPL treatment alone.
Conclusions: Our study suggests that lower concentration of ATF and TPL used in combination may produce a
synergistic anticancer efficacy that warrants further investigation for its potential clinical applications.
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XenograftBackground
Various proteolytic enzymes play important roles in
tumour invasion and metastasis process. These proteases
involve cathepsins, collagenases, plasmin, or plasmino-
gen activators [1]. Urokinase-type plasminogen activator
(uPA) and its receptor, uPAR, are important components
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reproduction in any medium, provided the orcapillary endothelial cells, and therefore play crucial
roles in the establishment, metastasis and angiogenesis
of most solid tumours [2,3]. uPA and uPAR are over-
expressed in diverse human malignant tumours in con-
trast to the corresponding normal tissue [4]. There are
several potential mechanisms underlying the promotion
of uPA and uPAR to tumour growth and invasion.
Firstly, binding of uPA to uPAR leads to activation of
plasminogen to plasmin, and the plasmin in turn acti-
vates latent matrix metalloproteases (MMPs) to dissolve
the components of extracellular matrix (ECM) and the
basement membrane [5,6]. Secondly, the binding of uPA. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Production and characterization of ATF. (A) Purified
ATF was analyzed by SDS-PAGE. Lane 1 protein Marker, ATF
migrated around 15 kDa (Lane 2). (B) Identity of the protein was
confirmed by Western blotting using poly-antibody against ATF.
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cules via some growth factor receptors, such as integrins
and EGFR, and then stimulate cell mobility and growth
[7,8]. Finally, uPA-uPAR system is implicated in tumour-
associated angiogenesis [9,10]. All these crucial roles of
uPA-uPAR system in tumour growth and metastasis
make it an ideal candidate for targeted cancer therapy.
Therapeutic molecules aimed at interrupting the inter-
action of uPA and uPAR may inhibit both tumour cell
invasiveness and tumour-associated angiogenesis,
thereby might be effective in cancer therapy. For ex-
ample, the monoclonal antibody against uPA or uPAR
has been confirmed effective to inhibit the proliferation,
migration and invasiveness of cancer cells in vitro
[11,12]. Another known antagonist inhibitor of uPA-
uPAR is ATF, the amino-terminal fragment of urokinase
which harbours an epidermal growth factor (EGF)-like
domain and a kringle domain. ATF could efficiently in-
hibit angiogenesis and tumour invasion in vitro and
in vivo by competing with uPA for binding to both
endothelial and tumour cell surfaces [13-15].
The Chinese herb Tripterygium wilfordii Hook F (TWHF)
has been used for centuries in the treatment of rheumatoid
arthritis and several other autoimmune and inflammatory
diseases [16-18]. Triptolide (TPL; C20H24O6), a diterpenoid
triepoxide, is purified from TWHF, which has been found to
possess potent immunosuppressive and anti-inflammatory
properties [19]. The antitumor activity of TPL was first
reported 40 years ago, when it was observed to induce cell
apoptosis in leukaemia. TPL has since attracted much re-
search interest [20]. TPL has been observed to inhibit the
proliferation of several types of cancer cells in vitro and to
reduce the growth and metastasis of tumours in vivo [21].
Results from in vivo studies indicate that TPL inhibits
tumour xenografts in nude mice from several human cancer
cell lines, including melanoma, bladder cancer, breast cancer,
and gastric and colorectal carcinoma [22,23]. Not only can
TPL inhibit tumour growth directly in vitro and in vivo but
it can also be efficacious as an adjunct agent for enhancing
the antitumor effects of chemotherapeutic or other cytotoxic
agents [24-26]. However, the therapeutic potential of TPL is
still limited due to its strong toxicity [27,28].
The combined inhibitory effects of TPL and other anti-
cancer drugs on tumour cell growth were reported to be su-
perior to the effects of these agents used singly [24,29].
Considering the antitumor activity of both ATF and TPL,
we therefore hypothesized that the combination of TPL and
ATF would enhance apoptosis in human solid tumour cells.
The results presented in this study demonstrate that TPL
and ATF combined treatment synergistically induces apop-
tosis in several human solid tumour cell lines through
caspase-dependent pathway. In addition, combination of
TPL and ATF at a low dosage eliminates the cytotoxicity of
normal cells induced by the individual drugs at theireffective concentrations. The combined treatment of TPL
and ATF also show robust in vivo efficacy, which strongly
suggests that TPL has potential in modulating and enhan-
cing the apoptosis and anti-angiogenesis induced by ATF on
human solid tumour cells, especially colon cancer, and the
synergistic effects of their combination point to a more
promising modality for treating colon cancer.
Results
ATF expression and purification
The Pichia expression system was used to prepare ATF
in soluble form. After ammonium sulphate precipitation,
the target protein was concentrated in a small buffer
volume and significant removal of some contaminants
was achieved. In the ion exchange purification step, ATF
was eluted as a single homogenous peak at 0.2 M NaCl.
After the final step, the desired level of product purity
(> 98%) was achieved. The final yield was about 18 mg/L
culture. On SDS-PAGE, the mobility of the purified pro-
tein was found to correspond to a molecular weight of
about 15 kDa (Figure 1A). The purified protein was fur-
ther examined by Western blotting using anti-human
ATF antibody. As shown in Figure 1B, the ATF migrated
at 15 kDa as expected and no degradation was observed.
Effect of single drug exposure on the growth of human
HCT116 colon cancer cell line and A549 lung
adenocarcinoma cell line
The inhibition of proliferation by TPL and ATF of the
human HCT116 colon cancer cell line and A549 lung
adenocarcinoma cell line was assessed after 24 h of drug
exposure, following 24 h culture in drug-free medium.
As shown in Figure 2A, growth of the HCT116 and
A549 cells was significantly inhibited in a dose-
dependent manner in vitro (p < 0.05) by either drug
treatment alone. For HCT116 cells, the inhibition ratio
Figure 2 Effect of TPL and ATF on the growth of tumour cells in vitro. (A) Left, A549 and HCT116 Cells were treated with TPL at different
concentrations (0, 2.5, 5, 10, 20, 40 ng/mL) for 24 h, and the cell viability was assessed by MTT assay. Right, A549 and HCT116 cells were treated
with ATF at different concentrations (0, 5, 10, 20, 40, 80 nM) for 24 h, and the cell viability was assessed by MTT assay. (B) Combined effects of
TPL and ATF on growth of HCT116, MDA-MB-231, A549, HeLa, and HEK293 cells. HCT116, MDA-MB-231, A549, HeLa, and HEK293 cells were
exposed to TPL (10 ng/mL) and/or ATF (10 nM) for 24 h. Combined treatment resulted in significant growth inhibition of tumour cells, more than
that by either drug alone; the degree of cytotoxicity in normal cells was not significant. Each bar shows the mean ± SD of three independent
experiments, performed in triplicate. *p < 0.05, **p < 0.01.
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TPL, and 69.2 ± 1.65% at the concentration of 40 ng/mL.
ATF at 5 nM had an inhibition ratio of 1.5 ± 0.42%, while
the ratio was 34.2 ± 1.32% at 80 nM. In this study, we
used the concentration at which ATF did not induce
proliferation inhibition on its own. Therefore, in the
subsequent combined treatment we choose ATF at the
concentration of 10 nM and TPL at a low dosage of
10 ng/mL.
Combined effect of TPL and ATF on growth of tumour
cells
In order to assess the combined effect of TPL and ATF
on tumour cell proliferation, MTT assay was performed.
Four solid tumour cell lines and a normal cell line were
treated with ATF (10 nM), TPL (10 ng/mL) or the com-
bination for 24 hours. As shown in Figure 2B, ATF treat-
ment alone did not cause obvious growth inhibition in
all cell lines. TPL treatment alone induced 15-20%inhibition ratio, however, addition of ATF led to a sig-
nificant increase in inhibition ratio (40-50%) as com-
pared to TPL alone (p < 0.05) and to ATF alone (p <
0.01) in tumour cell lines. The combination index (CI)
was 0.681 for HCT116 cells, 0.721 for MDA-MB-231
cells, 0.625 for A549 cells, and 0.721 for HeLa cells, indi-
cating their synergistic effect on inhibiting the prolifera-
tion of tumour cells at lower concentrations. In contrast,
no synergistic cytotoxicity was observed in HEK293
cells. These results showed that TPL at a subtoxic con-
centration had an enhanced effect on ATF-inhibited pro-
liferation of tumour cells without increasing cytotoxicity
to normal cells.
Combined effect of TPL and ATF on tumour cell apoptosis
To determine whether tumour cellular viability de-
creased with TPL and ATF via apoptosis, we mea-
sured the externalization of phosphatidylserine on the
cell membrane using Annexin V/PI staining. Two
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were exposed to ATF (10 nM), TPL (10 ng/mL) or a
combination of both (ATF 10 nM + TPL 10 ng/mL).
As shown in Figure 3A, after 24 h of treatment, ATF
alone had no obvious effect on tumour cell apoptosis,
while single therapy with TPL induced 15-25% apop-
tosis ratio. However, when HCT116 and A549 cells
were exposed to combined therapy with TPL and
ATF, the number of cells undergoing apoptosis signifi-
cantly increased (55-65%). This effect was statistically
significant as compared to single therapy with either
drug alone.
Regulatory mechanisms of TPL and ATF-induced
apoptosis in HCT116 cells
To explore the mechanisms of TPL and ATF-induced
apoptosis in HCT116 cells, activation of caspases andFigure 3 Effects of TPL and ATF on tumour cell apoptosis and caspas
and/or ATF (10 nM). Twenty-four hours later, all cells were harvested for flow cy
percentages of apoptosis cells. The experiments were carried out independent
V/PI double staining profile of A549 cells is also included. (B) Cleaved caspase-3
different treatment conditions. (C) Activity of caspase-3 and caspase-9 in HCT11
are presented as fold increases as determined by quantitative analysis. (D) Viab
treated with inhibitors for 2 h before the 24 h treatments, after which cell viabi
independent experiments. *p< 0.05, **p< 0.01.expression of pro-apoptotic proteins were analyzed by
Western blotting assay. Caspases are the main enzymes
that mediate apoptosis. Any stimuli that triggers apop-
tosis eventually leads to the activation of the effector
caspases, including caspase-3, caspase-6, and caspase-7.
In cells treated for 24 h, only the combined treatment
with TPL and ATF significantly enhanced the cleavage of
procaspase-3 and the downstream PARP, while treat-
ment with TPL or ATF alone caused minimal proteolytic
processing of procaspase-3 and cleavage of PARP. In
addition, combined treatment of HCT116 cells with TPL
and ATF noticeably increased the levels of BAX, BAK
and BAD with a prominent reduction of cIAP level
(Figure 3B). Caspase activity, shown in Figure 3C, indi-
cated that caspase-3 and caspase-9 activities were ele-
vated to 1.6- and 1.3-fold over controls in cells treated
with ATF and 8.5- and 4.7-fold over that in combinede activation. (A) A549 and HCT116 cells were exposed to TPL (10 ng/mL)
tometry analysis. Annexin V/PI-stained cells were analyzed with the
ly in triplicate; representative data are shown. *p< 0.05, **p < 0.01. Annexin
, PARP, cIAP, BAX, BAD, and BAK expressions in HCT116 cells under
6 cells treated with TPL and ATF alone or in combination for 24 h. Data
ility of HCT116 cells after treatment with caspase inhibitors. Cells were
lity was determined by MTT assay. Data are representative of three
Figure 4 Effects of TPL and ATF on NF-κB and JNK signalling
pathway. (A) HCT116 cells were treated with TPL and ATF alone or
in combination for 24 h. Nuclear proteins were extracted and
subjected to Western blotting for p65 detection. Lamin B was used
as loading control and α-tubulin was used as a cytoplasmic protein
marker to rule out cytoplasmic contamination in the nuclear
fraction. (B) HCT116 cells were treated with TPL and ATF alone or in
combination for 24 h. AKT, p-AKT, and c-FLIP proteins in whole cell
lysates were determined with specific antibodies. GAPDH was used
as loading control. (C) HCT116 cells were transfected with scramble
siRNA or NF-κB p65 siRNA. 48 h later, cell extracts were applied for
Western blotting analysis using NF-κB p65 and c-FLIP antibodies.
(D) HCT116 cells were treated with TPL and ATF alone or in
combination for 24 h. c-JUN, p-c-JUN and p-JNK protein in whole
cell lysates were determined with specific antibodies.
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inhibitors z-DEVD-FMK and z-LEHD-FMK abolished
caspase activation induced by TPL and ATF and rescued
HCT116 cells from treatment-induced cell death
(Figure 3C and 3D). Cell viability was also increased by
caspase inhibitors after combined treatment. These find-
ings indicate that activation of a caspase-involved apop-
totic pathway is one of the major mechanisms via which
TPL exerts its synergistic effect on ATF-treated HCT116
cells.
The cooperation of TPL with chemotherapy and cyto-
kines to induce apoptosis in cell lines has been attrib-
uted to inhibition of the NF-κB pathway [30]. Thus, we
investigated whether TPL at the dosage of 10 ng/mL
was able to modify the rate of NF-κB inhibition. Low
dosage of ATF or TPL alone had no obvious effect on
the expression of NF-κB/p65. However combined treat-
ment decreased the level of NF-κB/p65 in the nucleus of
HCT116 cells co-treated for 24 h (Figure 4A). c-FLIP,
one of the targeted genes of NF-κB, is known to inter-
fere with caspase activation downstream of death recep-
tors. To evaluate the combined effect of ATF and TPL
on c-FLIP expression, we treated HCT116 cells with
ATF in the absence or the presence of TPL. Our
Western blotting assay showed that combined treatment
decreased c-FLIP expression, while ATF or TPL alone
had no effect on c-FLIP expression (Figure 4B). To fur-
ther determine whether NF-κB inhibition resulted in re-
duction of c-FLIP, HCT116 cells were transfected with
NF-κB p65 siRNA. Western blotting analysis revealed
that siRNA against NF-κB p65 effectively reduced NF-
κB/p65 and c-FLIP-L levels in the transfected cells
(Figure 4C). AKT was reported to suppress apoptosis by
stimulating the transactivation potential of the RelA/p65
subunit of NF-κB [31,32]. Therefore, the detection of
Ser473 p-AKT and total AKT in HCT116 cells was
performed following exposure to TPL and ATF for 24 h.
Figure 4B revealed that the phosphorylation level of
AKT was markedly decreased after co-treatment with
TPL and ATF, but not either drug alone. JNK is known
to promote apoptosis by many cellular stresses, includ-
ing oxidative stresses, and DNA-damaging agents [33]
and plays important roles in cell proliferation and apop-
tosis [34]. We hypothesized that JNK might be activated
by cellular stress induced by TPL and ATF combined
treatment. As expected, the level of phospho-JNK in-
creased in cells co-treated with TPL and ATF. Further-
more, the combination of TPL and ATF induced a slight
increase in the level of phospho-c-JUN in HCT116 cells
(Figure 4D). In contrast, low dosage of ATF or TPL
alone failed to activate the JNK-c-JUN pathway. Taken
together, these findings suggest that TPL and ATF co-
operatively induce apoptosis through the suppression of
NF-κB transcriptional activity, subsequently reduction ofc-FLIP expression, and activation of caspases-9/caspase-
3 and the JNK-c-JUN pathway.
TPL and ATF combined therapy initiated cell cycle arrest
at S phase in HCT116 cells
TPL has been reported to have the ability of inhibiting cell
proliferation to execute its antitumor effect. Thus, we
detected the effect of ATF, TPL or the combination on cell
cycle distribution. As shown in Figure 5, ATF treatment
alone had no effect on cell cycle distribution. However,
when cells were incubated with TPL, the cell population of
G0/G1 phase decreased from 55.3% to 29.8% and S phase
increased from 10.3% to 41.2%. When combined with ATF,
the cell population of S phase was similar to TPL treatment
alone with the ratio of 40.5%, and the cell population of
G2/M phase, an indicator of cellular mitosis or cell division,
dropped from 30.4% to 16.2% as compared to TPL single
treatment. The decrease in G2/M phase during the combin-
ation therapy was due to the increased cell cycle arrest in
G0/G1 phase (from 29.8% for TPL single treatment to
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indicate that the major effect of TPL on cell cycle is S phase
arrest, and ATF can reinforce the cell proliferation inhibition
effect of TPL by endowing with additional ability of G0/G1
cell cycle arrest.
Combined effect of TPL and ATF on HUVEC and HCT116
cell migration
In order to precisely characterize the effect of TPL and
ATF on endothelial cell and tumour cell migration,
serum stimulated haptotaxis motility, measured by the
transwell motility chamber assay, was used to examine
the effect of TPL and ATF on HUVEC and HCT116 cell
migration. As shown in Figure 6A, the cells migrating to
the lower membrane were stained and quantified. We
found that, at a low dosage, ATF or TPL alone showed
slight inhibition of cell migration. However, combined
treatment with TPL and ATF showed more significantFigure 5 Effect of TPL and ATF on cell cycle distribution.
(A) HCT116 cells were treated with TPL (10 ng/mL) and/or ATF (10 nM).
Twenty-four hours later, cells were fixed and stained with PI for flow
cytometry as described in Materials and Methods. DNA histograms were
modeled with CellQuest analysis software. The experiments were carried
out in triplicate and representative data are shown. (B) Phase percentages
for G0/G1, S, and G2/M are depicted by bar graph. Data represent mean
values of triplicate samples.inhibition of cell migration than single therapy alone,
which reduced the migration of HUVECs by 71.6% or
58.2% compared with control PBS group or ATF group,
respectively. Similar results were also obtained in
HCT116 cells. As we know, uPAR-dependent cell signal-
ling events impact cell migration and survival. To ex-
plore the mechanisms underlying TPL and ATF
combined effect on cell migration, Western blotting ana-
lysis was further accessed to determine the protein ex-
pression level of FAK and uPAR, which have been
demonstrated to play important roles in cell migration.
The results indicated that combined treatment with TPL
and ATF significantly decreased phosphorylation level of
FAK, while total FAK protein remained unchanged. In
contrast, TPL or ATF alone had no effect on the phos-
phorylation of FAK. Similar results were observed in
uPAR protein expression. Decreased expression level of
uPAR was found in co-treated cells, compared with ATF
or TPL treatment alone (Figure 6B).
uPA/uPAR system was reported to induce MMPs ac-
tivity in cancer cells and then promote cancer cell mi-
gration and metastatic potential [35]. Previous reports
suggested that down-regulation of uPAR decreased the
expression of MMP-2 and MMP-9 [36]. Consistently,
our qPCR results showed that combined treatment with
TPL and ATF decreased the mRNA level of MMP-9 in
HCT116 cells. However, no obvious inhibitive effect on
mRNA expression of MMP-2 was found in cells co-
treated with TPL and ATF (Figure 6C).
Combination of TPL and ATF retarded the development
of colon cancer xenografts in nude mice
The antitumor effect of TPL in combination with ATF
was analyzed in a xenograft tumour model by
transplanting HCT116 cancer cells into athymic nude
mice. On the 7th day post-implantation, mice were ran-
domly divided into 4 groups before the tumour was pal-
pated, with at least 8 tumour-bearing mice in each
group. Tumour volume was significantly reduced after
intraperitoneally injection of TPL and ATF for 21 days
as compared to TPL or ATF Monotherapy (Figure 7A).
Both TPL and ATF monotherapy also inhibited the
growth of xenograft tumours to some extent, but the ef-
fects were not as significant as those seen in the com-
bined treatment group. At the end of the study, we
removed the tumours and measured their weight for
each group. Combined treatment with TPL and ATF
clearly reduced tumour weight compared with the con-
trol group, ATF or TPL single treatment (Figure 7B).
Tumour doubling time was prolonged from 4.67 days in
mice receiving PBS, 6.12 days in mice receiving ATF,
6.43 days in mice receiving TPL to 9.05 days in mice re-
ceiving TPL + ATF (p < 0.05; CI = 1.36; Figure 7C), indi-
cating a supra-additive or synergistic effect of TPL and
Figure 6 Effect of TPL and ATF on cell migration. (A) Transwell assay. HUVECs and HCT116 cells were treated with TPL (10 ng/mL) and/or ATF (10
nM). After 16 h pretreatment and 9 h incubation in the upper chamber, the cells migrating to the lower membrane were stained and counted in five fields
with a magnification of × 100. N = 3, bar = 50 μm. The experiments were carried out in triplicate and representative data are shown. (B) Effects of TPL and
ATF on uPAR, FAK and p-FAK protein expression. HCT116 cells were treated with TPL (10 ng/mL) and/or ATF (10 nM). Twenty-four hours later, cells were
harvested for Western blotting analysis using indicated antibodies. The level of GAPDH served as the loading control. Band intensities were calculated using
software Image J. Relative intensities are also shown. Data represent mean values of triplicate samples. (C) HCT116 cells were treated with TPL (10 ng/mL)
and/or ATF (10 nM). Twenty-four hours later, cells were harvested for RNA extraction and quantitative real time PCR using primers specific for human MMP-2,
MMP-9, and GAPDH (internal control). Data represent mean values of triplicate samples. *p< 0.05, *p< 0.01.
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was observed in mice treated with TPL alone, ATF
alone, or TPL and ATF combined treatment
(Figure 7D), indicating that there is no obvious toxicity
for all of the treatment regimens. Furthermore, lightmicroscopy revealed that tumour tissues in mice receiv-
ing TPL and ATF displayed more severe necrosis than
control or TPL or ATF single therapy (Figure 7E). The
percentage of necrotic area in tumours increased from
12.7% in mice receiving PBS, 26.2% in mice receiving
Figure 7 The antitumor effect of TPL and ATF on the xenograft of colon cancer. HCT116 cells were injected subcutaneously into the dorsal
flanks of athymic nude mice. When tumors reached a size of approximately 50 mm3, mice were i.p. with ATF and TPL or the combination every
two day for a total of 21 day. (A) The tumor growth inhibitory effects of different treatments were compared. (B) At the end of the study, the
excised tumors from each group were weighed. (C) Tumour double time of each group. (D) The weight of nude mice from each group did not
change significantly during the experiment. (E) Determination of tumor necrosis after combined treatment with TPL and ATF. Tumour necrosis
areas are shown by H&E staining and observed under light microscope (× 100). The viable tumor cells are indicated by a green arrow. (F) Quota
of tumour necrosis. Tumour necrosis was determined by software Image J (NIH, USA). Two sections/mouse and three mice were prepared. (G, H)
Blood vessel density within tumour was characterized by anti-CD31 immunostaining using anti-mouse CD31 monoclonal antibody (G) and
determined by the average number of vessels in 3 regions of highest density at × 200 magnifications in each section (assay was repeated in 4
sections per mouse and 3 mice were tested) (H). All data are shown as mean ± SD. *p < 0.05, **p < 0.01.
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ceiving TPL + ATF (Figure 7F). TPL and ATF single
therapy or untreated control displayed tissue necrosis in-
terspersed with viable tumour cells, whereas TPL and
ATF combined treatment induced large areas of con-
tinuous necrosis within tumours (Figure 7E). Immuno-
histochemical studies further revealed that TPL and
ATF combined treatment markedly reduced the expres-
sion of CD31, a marker of neoangiogenesis (Figure 7G
and 7H), suggesting that combination of TPL and ATF
could inhibit tumour progression primarily through sup-
pressing tumour-related angiogenesis.Discussion
Colon cancer remains a major public health threat and
accounts for approximately 13% of all cancers [37]. More
effective treatments and earlier detection have led to im-
proved survival over recent decades. However, around
50% of newly diagnosed colon cancer patients will even-
tually progress due to micro metastases, and die of their
disease, in spite of the advances in surgical techniques
and radiotherapy. Therefore chemotherapy becomes one
of the most important means of extending the survival
of colon cancer patients. The development of cancer in-
volves a complex interplay among cellular processes,
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Combination therapy is now considered to be a standard
approach to chemotherapy [38]. There are many advan-
tages to combination therapy, including the targeting of
multiple critical molecular processes, delivery of lower
dose agents with lower toxicity, and increased patient
tolerance. The effectiveness of combination chemother-
apy has stimulated an interest in exploring drugs with
different modes of activity at lower dosages [39].
The coordinated interaction of different proteolytic
systems is important for tumour cell invasion and me-
tastasis [40]. The invasive capacity of tumour cells can
be suppressed by synthetic inhibitors against various
proteases or by plasminogen activator system antago-
nists. The uPA system has pivotal roles in tumour
growth, angiogenesis, and metastasis [41]. The binding
of uPA to uPAR has been shown to mediate various
other signalling cascades [42], although the role of these
cascades in tumour progression is poorly understood.
Since the uPA-uPAR system contributes to the invasion
and motility of several cell types associated with tumour
progression, the inhibition of the uPA-uPAR interaction
may have significant antitumor effects. ATF, the amino
terminal fragment of urokinase, has been demonstrated
to act as an angiostatic molecule that targets the uPA-
uPAR system and inhibits cell invasion and migration.
By blocking the attachment of uPA to uPAR, ATF could
effectively shut down the plasmin activation on the sur-
face of both tumour and activated endothelial cells,
which is essential for angiogenesis-related ECM degrad-
ation, new blood vessel formation, and accordingly the
invasive phenotype of primary tumours [14,15]. In a re-
cent study, the invasiveness of a highly metastatic hu-
man lung giant-cell carcinoma cell line transfected with
ATF cDNA was significantly inhibited in vitro, as was
the lung metastasis of implanted cells in a spontaneous
metastasis model [43]. Li et al. also showed that
adenovirus-mediated delivery of ATF suppressed growth
of xenografted MDA-MB-231 human breast cancer cells
grown in athymic mice [44]. These data suggests that
ATF is a good candidate for cancer therapy. Neverthe-
less, the clinical experience and treatment of other solid
tumours tell us that only a few solid tumours respond to
single agent-based therapy. Chronic exposure to chemo-
therapeutic agents can induce the selection of clones
that are resistant to that particular agent; therefore, over-
time tumour resistance can occur. Additionally, solid
organ tumours sometimes have intrinsic resistance to
the drug before any treatment has started. It cannot be
overemphasized that the probability that drug resistance
develops over the course of the disease decreases if dif-
ferent agents are combined. Combined therapy also al-
lows decreasing drug doses, decreasing the likelihood of
toxicity.TPL, a natural, active compound isolated from
Tripterygium wilfordii Hook F, is known to induce apop-
tosis in several cancer cell types by activating both the
extrinsic and intrinsic pathways of apoptosis in tumours
[21]. As a promising immune-suppressor, TPL has been
widely used in Chinese medicine. TPL has multiple
pharmacological activities, including anti-inflammatory,
immunosuppressive, male anti-fertility and anticancer
effects [45,46]. Research into its mechanisms of action
has revealed that it potently inhibits monocyte activa-
tion, activates caspases and other pro-apoptotic signal-
ling cascades, inhibits angiogenesis and reverses drug
resistance [47,48]. Recent studies demonstrate that TPL
also possesses anti-cancer activity and inhibits cancer
cell proliferation in vitro and in vivo [21]. Although TPL
alone was very effective to kill tumour cell lines, it is not
curative and the safe dose range for in vivo application is
relatively narrow. A major concern about using TPL for
clinical antitumor applications is its toxicity. Shamon
et al. [49] reported that TPL exerted a modest antitumor
activity when administered at a dose of 25 μg/mouse 3
times per week intravenously to nude mice carrying hu-
man breast tumors, but higher doses (50 μg/mouse)
were lethal, suggesting a narrow therapeutic window of
TPL treatment. Severe side effects happened in a recent
phase I clinical study using F60008 [50], which is a
semi-synthetic derivate of TPL, in patients with solid tu-
mours. In preliminary study, we found that i.p. adminis-
tration of 100 μg/kg doses of TPL exerted slight
antitumor effects, and that the mice treated with
100 μg/kg TPL did not show any obvious side effects.
However, weight loss, skin inflammation and vessel in-
flammation were observed in the mice treated with
400 μg/kg TPL, and higher doses of TPL displayed
stronger effects but the side effects were more severe
(data not shown). Therefore it would be much more
beneficial if it can be used at a relatively lower dose to
sensitize the cytotoxicity of other anti-cancer drugs. TPL
has been shown great value when used in combination
with other antitumor treatments, inducing higher levels
of cell death by increasing tumour cell sensitivity to
chemotherapy or radiation. Previous studies indicate that
TPL can efficiently enhance the cytotoxicity of some cy-
tokines and anti-cancer drugs [24,51,52].
Since both ATF and TPL exhibit antitumor activity,
we formulated the hypothesis that combined therapy
with these two drugs increases the effectiveness as com-
pared with single therapy. In this study, we tested the
in vitro and in vivo enhancing effect of TPL on the cyto-
toxicity of ATF in a panel of solid tumour cell lines.
Using MTT assay we found that TPL inhibited the
growth and proliferation of ATF-treated tumour cells
synergistically. Compared to TPL or ATF alone, low dos-
age of these two drugs in combination induced
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known to be programmed and finally executed by
caspase-3, through several signalling pathways involved
in apoptosis regulation. To further exploit the antitumor
mechanism of TPL and ATF, we detected the activation
of caspase-9, caspase-3 and NF-κB/p65. Our results indi-
cated that induced apoptosis of HCT116 cells by the
combination of TPL and ATF was mediated through
caspase-9/caspase-3 activation and NF-κB/p65 inhib-
ition. In turn, caspases activation led to PARP cleavage,
DNA damage and fragmentation, nuclear condensation,
and eventually, the induction of apoptosis. NF-κB/p65
that comprises a heterotrimer of p50 and p65 binds to
its inhibitory protein IκBα, thereby leading to the release
of the p50-p65 heterodimer, which then translocates to
the nucleus and associates with the promoter regions
of multiple target genes. In this study, we found that
TPL and ATF combined treatment can down-regulate
NF-κB/p65 protein expression and this finding is
consistent with that of other reports [53,54]. NF-κB is
generally considered to be a survival factor that activates
expression of various anti-apoptotic genes, e.g. Bcl-2,
Bcl-xL, Mcl-1 and c-FLIP that block apoptosis [55].
Inhibition of NF-κB will lead to down-regulation of the
NF-κB-regulated anti-apoptotic proteins, thereby
promoting apoptotic cell death. Indeed, combined treat-
ment with TPL and ATF significantly decreased the
expression of c-FLIP, a well-known anti-apoptotic pro-
tein, and finally led to cell apoptosis. It has been
reported that the ser/thr kinase AKT can promote NF-
κB activity [31,32]. In the current study, we found that
TPL and ATF combined treatment did not affect the
total expression of AKT, but significantly decreased the
phosphorylation level of AKT (Figure 4B). The inactiva-
tion of AKT may lead to transcriptional inhibition of
NF-κB, and the previously well-characterized down-
regulation of c-FLIP expression by inactivated NF-κB. In
addition, co-treatment with TPL and ATF also led to
JNK activation. The activation of JNK promotes apop-
tosis in a manner that is dependent on the cell type and
the context of the stimulus. In the past, the contribu-
tions of the NF-κB and JNK pathways to cell death have
been discussed independently. However, recent studies
have indicated that one of the anti-apoptotic functions
of NF-κB is to down-regulate JNK activation [56].
Therefore, we speculated that TPL and ATF in combin-
ation could activate JNK in tumor cells through inacti-
vating NF-κB, thus contributing to apoptosis. In
addition, the activation of JNK is also involved in the
down-regulation of c-FLIP-L [57]. Thus, the inhibition
of NF-κB, up-regulation of JNK activity and subse-
quently reduction of c-FLIP expression might contribute
to the increased sensitivity to TPL and ATF-mediated
apoptosis (Figure 8).Cell cycle regulation is closely linked to cell prolifera-
tion, and one of the notable features of a tumour is ab-
normal cell cycle management. TPL has previously been
shown to induce cell accumulation in the S phase
[52,58]. Cell apoptosis seems like to be closely associated
with the cell cycle arrest in S phase via accelerating cells
into S phase and hampering cells out from S phase. In
human colon cancer cells, we confirmed that TPL accu-
mulated cells in S phase and thus caused cell apoptosis.
When in combination with ATF, cells were maintained
the S phase arrest and the population of cells in G2/M
phase was decreased as compared to TPL single therapy.
Nevertheless, some researches demonstrated that TPL
treatment triggered a G0/G1 cell cycle arrest and apop-
tosis in gastric cancer and multiple myeloma cells
[19,59]. In our study, treatment with TPL alone caused S
phase arrest, not G0/G1 arrest in HCT116 cells. How-
ever, ATF could help TPL to restore its ability of G0/G1
arrest, meanwhile retain its S phase arrest. Taken to-
gether, these results indicate that the cell cycle phase ar-
rest TPL will induce is cancer cell type-specific and ATF
can enhance the cell cycle arrest ability of TPL, thus
eventually increasing cell apoptosis. In addition, NF-κB
also plays a crucial role on cell cycle by regulating key
proto-oncogenes, including Cyclin D1, c-Myc and Skp2
[60]. Thus, the inhibition of NF-κB may partially con-
tribute to cell cycle arrest by combined treatment with
TPL and ATF (Figure 8).
Cell motility is one of the prerequisites for the inva-
sion and metastasis of malignant tumours. Most cancer
patients do not die from local complications of their pri-
mary tumour growth, but rather from the development
and spread of the tumour. Therefore, metastasis is one
of hallmarks of malignant tumour and a major cause of
death among cancer patients. Several reports have indi-
cated that TPL can reduce the growth and metastasis of
tumours in vivo and in vitro, via inhibition of heat shock
protein 70 (HSP70), CXC chemokine receptor 4
(CXCR4), or uPAR [61-63]. In this study, we found that,
in the presence of ATF at a low concentration, the mo-
tility of tumour cells was decreased, which clearly dem-
onstrated that ATF alone could partially inhibit this step.
When combined with TPL, the inhibition of tumour
cells migration was significantly enhanced. Mohanam
et al. reported that a glioma cell line over-expressing
ATF exhibited impaired adhesion, motility and
colonization, the mechanism underlying those pheno-
types was the rearrangement of cytoskeleton [15]. Cell
motility is made up with successive attachment and de-
tachment. Upon the binding of uPA, uPAR is subjected
to directly interacting with vitronectin, and thereby im-
proved the cell adhesion and attachment [64,65]. In the
presence of PAI-1, the complex containing uPA-PAI-1-
uPAR will be engulfed by cell, accompanied with the
Figure 8 A working model for the synergistic effect of TPL and ATF on tumour cells. TPL and ATF cooperatively induce apoptosis through
caspase-dependent pathway and cell cycle arrest. In HCT116 cells, combined treatment with TPL and ATF at a low dosage inhibits AKT phosphorylation
and subsequently inactivates NF-κB. The inhibition of NF-κB leads to down-regulation of c-FLIP, activation of caspases-9/caspase-3 and JNK-c-JUN pathway,
and cell cycle arrest, which finally promotes cell apoptosis. In addition, the suppression of NF-κB leads to decreased expression of uPAR, MMP-9 and
phospho-FAK, thereby inhibiting tumor cell migration and invasion. Furthermore, ATF can segregate uPA from its receptor uPAR, thus blocking ECM
remodeling and anti-angiogenesis processes.
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ling of intact uPAR to cell surface. This process may in-
duce the occurrence of cell detachment [66].
Presumably, ATF slows the movement by impairing the
recycling of uPAR on the cell surface. Unlike uPA, ATF
is incapable of binding PAI-1 [66,67], which blocks the
uPAR recycling and attenuates the attachment-
detachment cycle. Therefore, cells overexpressing uPAR
may adapt to be quiescent upon the ATF binding. To
further clarify the mechanisms underlying combined ef-
fect of TPL and ATF on cell migration, we examined the
uPAR-dependent signalling pathway. We found that,
combined treatment with TPL and ATF led to inhibition
of uPAR and FAK phosphorylation significantly. Specif-
ically, treatment of HCT116 cells with ATF or TPL
alone did not affect the expression level of uPAR protein
and downstream FAK phosphorylation, thus indicating
that the inhibition of cell migration was not an additive
but indeed a cooperative effect of TPL and ATF. It is
reported that TPL inhibits uPAR expression via blocking
NF-κB signalling [63]. Thus, we speculated that low dos-
age of TPL and ATF in combination led to inhibition of
NF-κB, which finally down-regulated uPAR expression.
Furthermore, inhibition of NF-κB pathway may also
down-regulate uPA [68]. In mammary tumour cells, uPA
binding to uPAR activates FAK through a still unknown
partner molecule [69]. Thus, the down-regulation ofuPA and uPAR may lead to subsequent decreased phos-
phorylation level of FAK. Taken together, these results
provide evidence that TPL and ATF combination-
triggered inhibition of cell migration is probably medi-
ated through NF-κB-uPA/uPAR-FAK-dependent cell sig-
nalling pathways (Figure 8). Additionally, we found that
combined treatment of ATF and TPL decreased the
mRNA level of MMP9 but not MMP2 in HCT116 cells,
which are mainly involved in the metastasis process. On
the contrast, ATF or TPL single therapy had no obvious
effect on MMP-9 expression, indicating that the expres-
sion of MMP-9 is synergistically regulated by TPL and
ATF. Although MMP-9 shares fairly broad substrate spe-
cificity and structure features with MMP-2, both
enzymes differ considerably in terms of transcriptional
regulation. The 5′ flanking sequence of MMP-9 gene
harbors NF-κB binding sites, while the expression of
MMP-2 is mainly regulated by SP-1 [70]. The combined
effect of TPL and ATF on MMP-9 expression is prob-
ably through NF-κB inhibition. These could be pre-
sumed to be one of the reasons for different effect of
TPL and ATF on the gene expression of MMP-9, com-
pared with MMP-2.
uPA-uPAR system plays a crucial role in the ECM deg-
radation and remodelling in the process of angiogenesis,
thereby may affect the formation of neovessel structure
and the tumour development [3]. In the in vivo tumour
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growth by blocking the proteolytic cascade initiated by
uPA-uPAR interaction. Moreover, its antitumor effects
could be further enhanced by TPL at a low dosage,
suggesting a promising strategy to treat the devastating
disease. During the development of colon cancer within
nude mice, the tumour cells recruit murine endothelial
cells to establish a network of new blood vessel. Human
and mouse ATF are species specific. When entering into
the circulation system, ATF was speculated to target
only tumour cells instead of both the tumour and
endothelial cells. Therefore, the anti-angiogenesis and
antitumor activity may be partially compromised. We as-
sumed that the antitumor function of ATF was achieved
by its suppressive capacity against angiogenesis, which
owes to its competitive interaction with uPAR towards
uPA. In this case, TPL does not show species specific
and can target both tumour and endothelial cells. Thus,
when combined with TPL, ATF induced significantly in-
creased antitumor and anti-angiogenesis efficiency. It is
worth paying attention that only one colon cancer cell
line was investigated in in vivo experiment in this study.
More cancer cell lines are required to be studied in vivo
to evaluate the therapeutic application of TPL and ATF
combination on cancer in future.
Conclusions
In summary, we provided evidence that TPL potently
inhibited the growth of human solid tumour cell lines
in vitro. We have also demonstrated that TPL, at a low
concentration, synergistically induced cell apoptosis
through multiple targets including caspases and NF-κB
pathways in various tumour cell lines when combined
with ATF (Figure 8). Furthermore, combined treatment
with the two drugs effectively reduced growth of
xenografted HCT116 cells grown in athymic mice with-
out exhibiting any toxicity in the animals. Based on the
synergistic antitumor activity profiles of combined TPL
and ATF treatments in vitro and in vivo and the absence
of cytotoxicity in normal tissues, we believe that TPL
has strong therapeutic value for use in combination with
ATF against colon cancer.
Methods
Cells, cell culture, and reagents
Human A549 lung adenocarcinoma cell line, human
HCT116 colon cancer cell line, human breast cancer meta-
static cell MDA-MB-231, human cervical carcinoma HeLa
cell line, human embryonic renal HEK293 cells and human
umbilical vein endothelial cells (HUVECs) were purchased
from the American Type Culture Collection (ATCC, Phila-
delphia, PA, USA). MDA-MB-231, HeLa and HEK293 cells
were grown in Dulbecco’s modified Eagle’s medium
(DMEM) (HyClone, Logan, UT, USA) supplemented with10% (v/v) fetal bovine serum (HyClone, Logan, UT, USA)
and 1% penicillin-streptomycin (Invitrogen, Carlsbad, CA,
USA). A549 and HCT116 cells were grown in RPMI 1640
(HyClone, Logan, UT, USA) supplemented with 10% (v/v)
fetal bovine serum (HyClone, Logan, UT, USA) and 1%
penicillin-streptomycin (Invitrogen, Carlsbad, CA, USA).
HUVECs were grown in Medium 200 (Cascade Biologics,
Portland, OR, USA) supplemented with Low Serum
Growth Supplement (LSGS). All cells were cultured in a
humidified CO2 incubator at 37°C. TPL (99% purity,
Sigma-Aldrich, St. Louis, MO, USA) was solubilised in
0.01% dimethyl sulfoxide (DMSO) in phosphate buffered
saline (PBS), filtered through a 0.2 μm Millipore filter and
kept at −70°C. Annexin V and propidium iodide (PI) were
purchased from Molecular Probes (Eugene, OR, USA).
Expression and purification of ATF in Pichia pastoris
The plasmid pGAPZαA-ATF for the expression of ATF
was constructed previously in our laboratory by Dr.
Jianping Li. Plasmid DNA was then linearized at the Bln
I site and electroporated into the yeast host strain X-33
(Invitrogen, Carlsbad, CA, USA). Recombinants were se-
lected on YPDS plates (10 g/L yeast extract, 20 g/L pep-
tone, 20 g/L dextrose, 20 g/L agar, and 1 M sorbitol) and
characterized for expression of ATF. A single positive
clone of Zeocin-resistant was selected with a view to
produce the specific protein. A preculture growth step
was performed for 24 h in a 250 mL Erlenmeyer flask
containing 50 mL YPD medium. This cell culture was
further used to inoculate larger yeast cell cultures at an
optical density (OD600 nm) of 1, to start the cell growth
directly in the exponential growth phase, as well as to
establish reproducible cell culture conditions. The yeast
was further grown at 30°C with orbital agitation at a rate
of 250 rpm. The optimum YPD medium to flask volume
ratio for ATF production was found to be 1/5 and the
cultures were usually performed in a 1-L Erlenmeyer
flask containing 200 mL YPD medium without any
Zeocin. The cultures were stopped after 72 h and the
cells were pelleted by centrifugation at 3000 × g for
20 min. Culture supernatants from shaker flasks were
precipitated with ammonium sulphate (65% saturation).
The precipitate was then dissolved in buffer A (20 mM
sodium acetate, 1 mM EDTA, 0.5 mM PMSF, pH 4.8),
and finally dialyzed against the same buffer at 4°C. Fur-
ther purification was carried out by CM Sepharose Fast
Flow column (GE Healthcare). After loading the sample,
the column was washed with buffer B (20 mM sodium
acetate, 1 mM EDTA, pH 4.8) and stepwise eluted by
0.1 M, 0.2 M, 0.5 M NaCl in buffer B. The eluted frac-
tions were pooled and the concentration of ATF was de-
termined by the Bio-Rad protein assay method (Bio-Rad,
Hercules, CA). The purity was determined on a SDS-
PAGE gel stained with Coomassie Blue. The identity of
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clonal mouse anti-ATF antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA).
Cell proliferation assay
The effects of ATF, TPL or the combination on cell prolifer-
ation were assessed by the MTTassay. Cells in the exponen-
tial growth phase were seeded into a 96-well plate at a
density of 5000 cells per well. After 24 h, ATF (10 nM), TPL
(10 ng/mL) or the combination were added to the medium.
The cells were incubated at 37°C for 24 h, then the cell via-
bility was determined by the colorimetric MTT [3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium brom-
ide] assay at wave length 570 nm by TECAN Safire Fluores-
cence Absorbance and Luminescence Reader (Vienna, VA,
USA). The cell viability was calculated according to the for-
mula: Cell viability (%) = average A570 nm of treated group/
average A570 nm of control group × 100%. Each experiment
was performed in quadruplicate and repeated at least three
times. To determine whether TPL in combination with ATF
worked synergistically, the combination index (CI) in MTT
assay was calculated as follows: CI = AB / (A × B).
According to cell viability of each treatment, AB is the ratio
of the combination treatment to the control treatment; A or
B is the ratio of the single agent treatment to the control
treatment. Thus a CI value less than, equal to or greater
than 1 indicates that the drugs are synergistic, additive or
antagonistic, respectively. A CI less than 0.7 indicates that
the drugs are significantly synergistic.
Annexin V-fluorescein isothiocyanate/propidium iodide
assay
To quantify the percentage of cells undergoing apoptosis,
we used the Annexin V-FITC kit as described by the manu-
facturer. Briefly, HCT116 and A549 cells were incubated for
24 hours with TPL (10 ng/mL) and ATF (10 nM) alone or
in combination. Next, the treated cells were collected and
trypsinized for 3–5 min. The digested cells were washed
twice with cold PBS and resuspended in binding buffer at a
concentration of 1 × 106 cells/mL. After incubation, 100 μL
of the solution was transferred to a 5 mL culture tube, and
5 μL of Annexin V-FITC and 10 μL of PI were added. The
tube was gently centrifuged and incubated for 15 min at
room temperature in the dark. At the end of incubation,
400 μL of binding buffer was added, and the cells
were analyzed immediately by flow cytometry (BD
Biosciences, CA, USA). Flow cytometry analysis was
performed with untreated HCT116 and A549 cells as
control.
Cell cycle analysis
HCT116 cells (2 × 106) were treated with TPL (10 ng/mL)
and ATF (10 nM) alone or in combination for 24 h. Cells
were then harvested, washed in PBS, resuspended gentlyin 5 mL of 100% ethanol, and fixed at 25°C for 1 h. After
washing with PBS, cells were incubated with DNase-free
RNase A (200 μg/mL) at 37°C for 1 h and washed with
PBS. PI (10 μg/mL) was added and the cells were incu-
bated at 37°C for 5 min. The distribution of cells with dif-
fering DNA content was analyzed on a FACSCalibur flow
cytometer with CellQuest software (BD Biosciences, CA,
USA) at an excitation wavelength of 530 nm. Fluorescence
emission was measured using a 620 nm band pass filter.
Caspase activity assay
Caspase-3 and caspase-9 activities were measured using
colorimetric activity assay kits (Chemicon International,
CA, USA). The assay is based on the cleavage of the
chromogenic substrates, DEVD-pNA and LEHD-pNA,
by caspase-3 and caspase-9, respectively. Cells were
lysed in chilled lysis buffer on ice for 10 min and
centrifuged for 5 min at 10,000 × g. Caspase substrate
solution containing the specific peptide substrate was
then added to the supernatant and incubated for 2 h at
37°C before measurement by ELISA reader at 405 nm.
RNA interference
The siRNA against NF-κB p65 (sc-29410) was purchased
from Santa Cruz Biotechnology, Santa Cruz, CA. For
transfection with siRNAs, logarithmically growing cells
were transfected with siRNA as instructed by the
manufacturer.
Western blot analysis
HCT116 cells were incubated with TPL (10 ng/mL) and
ATF (10 nM) alone or in combination for 24 h, then lysed
with RIPA buffer (Beyotime, China) with protease inhibitor
cocktail tablets (Complete Mini, EDTA free; Roche, Basel,
Switzerland). Supernatants were collected and protein con-
centration was determined by the Bio-Rad protein assay
method (Bio-Rad, Hercules, CA). Western blotting was
performed according to standard protocols. Proteins were
separated by SDS-PAGE and transferred onto nitrocellulose
membranes that were blocked with 5% non-fat milk in TBS
containing 0.1% Tween 20, and incubated with primary
antibodies: p-FAK (Tyr 397), FAK, p-JNK, c-JUN, p-c-JUN,
p-AKT (Ser 473), uPAR, cleaved caspase-3 (Cell Signalling
Technology, Beverly, MA, USA), NF-κB p65 (Invitrogen,
Carlsbad, CA), BAX, BAD, BAK, cIAP, poly (ADP-ribose)
polymerase (PARP), α-tubulin, c-FLIP-L, GAPDH, Lamin B
(Santa Cruz Biotechnology, Santa Cruz, CA). Secondary
antibodies were coupled to horseradish peroxidase, and
were goat anti-rabbit or goat anti-mouse. Bound antibodies
were then visualized with ECL plus Western blotting detec-
tion reagents (GE Healthcare). Signal intensity was quanti-
fied by densitometry using the software Image J (NIH,
Bethesda, MD). All experiments were done in triplicate and
performed at least three times independently.
Lin et al. Molecular Cancer 2013, 12:54 Page 14 of 16
http://www.molecular-cancer.com/content/12/1/54RNA extraction and quantitative real-time PCR
Total RNA was extracted from treated cells using a
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) follow-
ing the manufacturer’s instructions and was used to pre-
pare cDNA by PrimeScript RT reagent Kit (Takara,
Otsu, Shiga, Japan). Quantitative real-time PCR was
performed with SsoFast EvaGreen Supermix on a CFX96
Real-Time System (Bio-Rad Laboratories, Hercules,
CA, USA). The sequences of PCR primers used in our
study were synthesized commercially, and are shown
as follows: MMP-2 upstream: 5′ -CCGTCGCCCA
TCATCAA- 3′; MMP-2 downstream: 5′ GGTATTGCA
CTGCCAACTCTTTG- 3′; MMP- upstream: 5′ GGA
CGATGCCTGCAAGT- 3′; MMP-9 downstream: 5′ -A
CAAATACAGCTGGTTCCCAATC- 3′. The glyceralde-
hyde 3-phosphatase dehydrogenase (GAPDH) gene was
used as the reference gene. All data were means of fold
change of triplicate analysis and normalized with those
of GAPDH.
Cell migration assay
The effects of ATF, TPL or the combination on endothe-
lial cell and tumor cell migration were assessed by the
transwell assay. The cell migration assay was performed
using transwell inserts (8.0 mm pore size, Millipore,
Billerica, MA, USA) as described previously [71]. Before
the experiment, HUVECs and HCT116 cells had been
cultured in serum-free medium with ATF (10 nM), TPL
(10 ng/mL) or the combination (PBS used as buffer con-
trol) for 16 h. Then the cells were harvested and
resuspended in the same medium. 1 × 105 cells in a vol-
ume of 0.1 mL were added to the upper chamber, and
the lower chamber was filled with 0.6 mL of 20% FBS
supplemented medium. After incubation at 37°C for 9 h,
cells on the upper surface of the membrane were re-
moved. The migrant cells attached to the lower surface
were fixed in 10% formalin at room temperature for
30 min, and stained for 20 min with a solution
containing 1% crystal violet and 2% ethanol in 100 mM
borate buffer (pH 9.0). The number of cells migrating to
the lower surface of the membrane was counted in five
fields under a microscope with a magnification of × 100.
All groups of experiments were conducted in triplicate,
and the cell number was counted by Image-Pro Plus 6.0
software.
In vivo animal tumour model experiment
Athymic nude mice (6–8 weeks of age) were obtained
from Shanghai Laboratory Animal Centre (Shanghai,
China) and housed under germfree conditions. Animal
care and use were performed strictly in accordance with
the ethical guidelines by Nanjing University Animal Care
and Use Committee and the study protocol was ap-
proved by the local institution review board. HCT116cells (2 × 106 cells in 50 μL) were injected subcutane-
ously into the dorsal flanks of mice. Tumour volume
was monitored by measuring the two maximum perpen-
dicular tumour diameters with callipers every alternate
day. All tumour-bearing mice were divided randomly
into 4 groups, and treatment was initiated on the 7th
day when the volume of tumour reached a size of ap-
proximately 50 mm3. The mice were injected intraperi-
toneally (i.p.) with ATF (100 nmol/kg), TPL (100 μg/kg)
or the combination every two day for a total of 21 day.
Control mice received i.p. injection of PBS. Antitumor
activity of treatments was evaluated by tumour growth
inhibition. Tumours were measured individually with a
calliper every other day, and the formula, tumour
volume = length × width2 × 0.52 was used to mimic the
tumour volume. At the end of study, the tumours were
collected and weighed.
In a parallel animal assay (totally 4 groups, and 3 mice
per group), the tumour establishment and drug treat-
ment are the same as described earlier. On the 21th day,
mice were euthanized. Tumours were collected, fixed
with 4% formaldehyde, embedded in paraffin and
sectioned for haematoxylin and eosin (H&E) staining or
immunostaining according to standard histological pro-
cedures. Blood vessel within tumours was immuno-
stained with anti-mouse CD31 monoclonal antibody (BD
Pharmingen, Franklin Lakes, NJ, USA) and determined
by the average number of vessels in 3 regions of highest
density at 200 ×magnifications in each section.
Calculation of tumour doubling time and combination
index
The tumour doubling time (TDT) and combination index
(CI) were calculated using GraphPad Prism v 5.0. TDT
values were generated from exponential growth curves,
which had been fitted to % change in tumour volume data
(r2 > 0.70). Our CI calculations were adapted [72] to apply
to TDT values. First, the TDT value for untreated mice was
subtracted from the TDT value for each treatment group to
obtain ‘blanked’ TDT values (TDTB). Then, the CI was cal-
culated as the ratio of TDTB values of combination treat-
ment to individual treatments: CI = (TDTB combination of
TPL and ATF)/(TDTB TPL alone + TDTB ATF alone).
Statistical analysis
Statistical analysis was carried out using the SPSS soft-
ware (version 11.0; SPSS, Chicago, IL). Data were
expressed as the mean ± standard deviations (SD) and
analyzed by one-way ANOVA and the least significant
difference tests. P < 0.05 was considered statistically
significant.
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